uniQure (QURE) Competitors

uniQure (NASDAQ:QURE) and Protagonist Therapeutics (NASDAQ:PTGX) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their earnings, valuation, risk, institutional ownership, dividends, profitability, media sentiment, community ranking and analyst recommendations.

Is QURE or PTGX more profitable?

Protagonist Therapeutics has a net margin of 52.76% compared to uniQure's net margin of -837.80%. Protagonist Therapeutics' return on equity of 34.68% beat uniQure's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
uniQure	-837.80%	-188.82%	-32.17%
Protagonist Therapeutics	52.76%	34.68%	30.98%

Do analysts rate QURE or PTGX?

uniQure currently has a consensus target price of $37.82, indicating a potential upside of 134.24%. Protagonist Therapeutics has a consensus target price of $65.44, indicating a potential upside of 18.96%. Given uniQure's higher probable upside, analysts plainly believe uniQure is more favorable than Protagonist Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
uniQure	0 Sell rating(s)	3 Hold rating(s)	6 Buy rating(s)	2 Strong Buy rating(s)	2.91
Protagonist Therapeutics	0 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	3.00

Do institutionals & insiders have more ownership in QURE or PTGX?

78.8% of uniQure shares are held by institutional investors. Comparatively, 98.6% of Protagonist Therapeutics shares are held by institutional investors. 4.8% of uniQure shares are held by insiders. Comparatively, 4.9% of Protagonist Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Which has preferable valuation and earnings, QURE or PTGX?

Protagonist Therapeutics has higher revenue and earnings than uniQure. uniQure is trading at a lower price-to-earnings ratio than Protagonist Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
uniQure	$20.20M	43.78	-$308.48M	-$4.39	-3.68
Protagonist Therapeutics	$207.80M	16.41	-$78.96M	$0.75	73.35

Does the media favor QURE or PTGX?

In the previous week, Protagonist Therapeutics had 2 more articles in the media than uniQure. MarketBeat recorded 9 mentions for Protagonist Therapeutics and 7 mentions for uniQure. Protagonist Therapeutics' average media sentiment score of 0.80 beat uniQure's score of 0.53 indicating that Protagonist Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
uniQure	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Protagonist Therapeutics	4 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Does the MarketBeat Community favor QURE or PTGX?

uniQure received 371 more outperform votes than Protagonist Therapeutics when rated by MarketBeat users. Likewise, 70.71% of users gave uniQure an outperform vote while only 61.55% of users gave Protagonist Therapeutics an outperform vote.

Company	Underperform	Outperform
uniQure	Outperform Votes 664 70.71%	Underperform Votes 275 29.29%
Protagonist Therapeutics	Outperform Votes 293 61.55%	Underperform Votes 183 38.45%

Which has more volatility & risk, QURE or PTGX?

uniQure has a beta of 0.08, indicating that its share price is 92% less volatile than the S&P 500. Comparatively, Protagonist Therapeutics has a beta of 2.25, indicating that its share price is 125% more volatile than the S&P 500.

Summary

Protagonist Therapeutics beats uniQure on 14 of the 19 factors compared between the two stocks.